株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

認識機能障害:パイプライン製品の分析

Cognitive Impairment - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 199740
出版日 ページ情報 英文 288 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
認識機能障害:パイプライン製品の分析 Cognitive Impairment - Pipeline Review, H2 2016
出版日: 2016年09月21日 ページ情報: 英文 288 Pages
概要

認識機能障害とは、知的障害とも言われますが、記憶、新しいことの学習、集中もしくは毎日の生活に影響を及ぼす意思決定に問題を抱える状態を特徴とします。症状には、記憶障害、視覚問題、気分の落ち込み、怒りやすい状態と攻撃性、不安、および無関心が含まれます。素因には、年齢、性別、家族歴が含まれ、また、種々の脳血管疾患との関連が濃厚なその他の主要なリスク因子(高血圧、高コレステロール血症、糖尿病および喫煙)は、認知機能障害の変性形態の一因となる可能性があります。

当レポートでは、世界各国での認識機能障害治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

認識機能障害の概要

治療薬の開発

  • 認識機能障害向けパイプライン製品:概要
  • 認識機能障害向けパイプライン製品:比較分析

各企業で開発中の認識機能障害治療薬

大学/研究機関で研究中の認識機能障害治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

認識機能障害治療薬:開発中の製品の一覧(企業別)

認識機能障害治療薬:研究中の製品の一覧(大学/研究機関別)

認識機能障害治療薬の開発に従事している企業

認識機能障害:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル(製品概要、機能メカニズム、研究開発(R&D)の進展状況)

認識機能障害治療薬:パイプライン製品の最新動向

認識機能障害治療薬:開発が休止状態の製品

認識機能障害治療薬:開発が中止された製品

認識機能障害関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8469IDB

Summary

Global Markets Direct's, 'Cognitive Impairment - Pipeline Review, H2 2016', provides an overview of the Cognitive Impairment pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment
  • The report reviews pipeline therapeutics for Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cognitive Impairment therapeutics and enlists all their major and minor projects
  • The report assesses Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cognitive Impairment

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Cognitive Impairment Overview
  • Therapeutics Development
  • Cognitive Impairment - Therapeutics under Development by Companies
  • Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes
  • Cognitive Impairment - Pipeline Products Glance
  • Cognitive Impairment - Products under Development by Companies
  • Cognitive Impairment - Products under Investigation by Universities/Institutes
  • Cognitive Impairment - Companies Involved in Therapeutics Development
  • Cognitive Impairment - Therapeutics Assessment
  • Drug Profiles
  • Cognitive Impairment - Dormant Projects
  • Cognitive Impairment - Discontinued Products
  • Cognitive Impairment - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Cognitive Impairment, H2 2016
  • Number of Products under Development for Cognitive Impairment - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Cognitive Impairment - Pipeline by AbbVie Inc, H2 2016
  • Cognitive Impairment - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Cognitive Impairment - Pipeline by AgeneBio Inc., H2 2016
  • Cognitive Impairment - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Astellas Pharma Inc., H2 2016
  • Cognitive Impairment - Pipeline by AstraZeneca Plc, H2 2016
  • Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Cognitive Impairment - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Cognitive Impairment - Pipeline by Cardax, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Cerecor Inc., H2 2016
  • Cognitive Impairment - Pipeline by CereSpir Incorporated, H2 2016
  • Cognitive Impairment - Pipeline by Cognition Therapeutics, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Confluence Pharmaceuticals LLC, H2 2016
  • Cognitive Impairment - Pipeline by Coronis Partners Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Cortice Biosciences, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Eisai Co., Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2016
  • Cognitive Impairment - Pipeline by Ensol Biosciences Inc., H2 2016
  • Cognitive Impairment - Pipeline by FORUM Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment - Pipeline by Genzyme Corporation, H2 2016
  • Cognitive Impairment - Pipeline by H. Lundbeck A/S, H2 2016
  • Cognitive Impairment - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Cognitive Impairment - Pipeline by IntelGenx Corp., H2 2016
  • Cognitive Impairment - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Iproteos S.L., H2 2016
  • Cognitive Impairment - Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment - Pipeline by Luc Therapeutics, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Merck & Co., Inc., H2 2016
  • Cognitive Impairment - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Neuralstem, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Neuron Biopharma SA, H2 2016
  • Cognitive Impairment - Pipeline by NLS Pharma Group, H2 2016
  • Cognitive Impairment - Pipeline by Octapharma AG, H2 2016
  • Cognitive Impairment - Pipeline by Omeros Corporation, H2 2016
  • Cognitive Impairment - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2016
  • Cognitive Impairment - Pipeline by Panacea Pharmaceuticals, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Pfizer Inc., H2 2016
  • Cognitive Impairment - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Sage Therapeutics, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Saniona AB, H2 2016
  • Cognitive Impairment - Pipeline by SeneXta Therapeutics SA, H2 2016
  • Cognitive Impairment - Pipeline by Shire Plc, H2 2016
  • Cognitive Impairment - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Spherium Biomed S.L., H2 2016
  • Cognitive Impairment - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Cognitive Impairment - Pipeline by Tetra Discovery Partners LLC, H2 2016
  • Cognitive Impairment - Pipeline by Therapix Biosciences Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Vanda Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment - Pipeline by Vicore Pharma AB, H2 2016
  • Cognitive Impairment - Pipeline by Virogenomics BioDevelopment, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cognitive Impairment - Dormant Projects, H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..1), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..2), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..3), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..4), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..5), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..6), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..7), H2 2016
  • Cognitive Impairment - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Cognitive Impairment, H2 2016
  • Number of Products under Development for Cognitive Impairment - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top